fig3
Figure 3. Tumor cell staining showing (A) high, (B) moderate, (C) low, and (D) negative PD-L1 membrane expression. Images taken at 40x magnification. As per FDA guidelines for Keytruda eligibility, tumors shown in (A-C) will be eligible for anti-PDL1 therapy.
